{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/ORMP",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# ORAMED PHARMACEUTICALS INC. (NASDAQ: ORMP) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is ORAMED PHARMACEUTICALS INC., listed on NASDAQ under ticker ORMP, with ISIN US68403P2039 and LEI 5299006K52ZIIGQJ6R84. Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States, Delaware. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 63 filings in the twelve months from 2025-11-08 to 2026-11-08, across 34 filing days. The median gap between filing days is 6 days. The median latency from the latest filing to the record date is 37 days, against an exchange median of 5.0 days and a sector median of 4.0 days. The exchange median cadence gap is 6.0 days and the sector median cadence gap is 6.0 days. The latest filing is dated 2026-10-02 and is of type directors_dealings.\n\n## Auditor\n\nThe auditor of record is Kesselman & Kesselman C.P.A.s, located in Tel Aviv, Israel. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds one lifecycle line: a listing dated 2025-11-17. It holds no delisting, no name change, and no segment move. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag is listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nNo research houses were found on the issuer's own investor-relations pages read. The count is 0.\n\n## Open research\n\nThe record holds 8 openly published research notes. Zacks Small-Cap Research published 6 of them, dated 2022-11-21, 2022-04-28, 2021-11-10, 2020-12-10, 2020-01-07 and 2019-05-07. A.G.P. / Alliance Global Partners published one dated 2020-12-03. MLV published one dated 2014-01-07.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe record holds sealed years 2021, 2022, 2023, 2024, 2025 and 2026 for this issuer. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n17 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest (identity.isin)\n- https://data.sec.gov/submissions/CIK0001176309.json (identity.jurisdiction)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/ORMP (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://oramed.com/wp-content/uploads/2022/11/Zacks-Report-Nov.-2022.pdf (open research)\n- https://oramed.com/wp-content/uploads/2022/06/Zacks-Report-April-28-2022.pdf (open research)\n- https://oramed.com/wp-content/uploads/2022/06/Zacks_SCR_Research_November-11-2021.pdf (open research)\n- https://oramed.com/wp-content/uploads/2022/06/Zacks-Update-Dec-2020-1.pdf (open research)\n- https://oramed.com/wp-content/uploads/2022/06/AGP-initiating-coverage-ORMP-Dec-2020.pdf (open research)\n- https://oramed.com/wp-content/uploads/2022/06/Zacks-Update-Jan-7-2020.pdf (open research)\n- https://oramed.com/wp-content/uploads/2022/06/Zacks-SCR-Research-Update-May-2019.pdf (open research)\n- https://oramed.com/wp-content/uploads/2022/06/MLV-Initiating-Coverage-7-Jan-2014.pdf (open research)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/ORMP (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm",
    "state": "sourced",
    "value": "Kesselman & Kesselman C.P.A.s"
   },
   "auditor_firm_id": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm",
    "state": "sourced",
    "value": "1309"
   },
   "auditor_location": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm",
    "state": "sourced",
    "value": "Tel Aviv, Israel"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/ORMP",
  "coverage": {
   "count": 0,
   "houses": [],
   "pages_checked": [
    {
     "page": "https://oramed.com/investor-relations/",
     "result": "read: 0 of 0 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": null,
   "state": "none_found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "agm_egm": 3,
    "corporate_news": 7,
    "director_change": 1,
    "directors_dealings": 29,
    "regulatory_filing": 18,
    "results": 5
   },
   "cadence_median_gap_days": 6,
   "filing_days": 34,
   "filings": 63,
   "latency_days": 37,
   "latest": [
    {
     "category": "4",
     "date": "2026-10-02",
     "source": "https://www.sec.gov/Archives/edgar/data/1176309/000121390026106531/xslF345X06/ownership.xml",
     "title": "4",
     "type": "directors_dealings"
    },
    {
     "category": "4",
     "date": "2026-10-02",
     "source": "https://www.sec.gov/Archives/edgar/data/1176309/000121390026106530/xslF345X06/ownership.xml",
     "title": "4",
     "type": "directors_dealings"
    },
    {
     "category": "144",
     "date": "2026-10-01",
     "source": "https://www.sec.gov/Archives/edgar/data/1176309/000197640826000877/xsl144X01/primary_doc.xml",
     "title": "144",
     "type": "regulatory_filing"
    },
    {
     "category": "144",
     "date": "2026-10-01",
     "source": "https://www.sec.gov/Archives/edgar/data/1176309/000197640826000876/xsl144X01/primary_doc.xml",
     "title": "144",
     "type": "regulatory_filing"
    },
    {
     "category": "4",
     "date": "2026-09-25",
     "source": "https://www.sec.gov/Archives/edgar/data/1176309/000121390026103540/xslF345X06/ownership.xml",
     "title": "4",
     "type": "directors_dealings"
    }
   ],
   "latest_filing_date": "2026-10-02",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/ORMP",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (ISINs mapped to the LEI)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest",
    "state": "sourced",
    "value": "US68403P2039"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001176309.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-08",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN US68403P2039)",
    "state": "sourced",
    "value": "5299006K52ZIIGQJ6R84"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001176309.json",
    "state": "sourced",
    "value": "ORAMED PHARMACEUTICALS INC."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001176309.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001176309.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "ORMP"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [
    {
     "date": "2025-11-17",
     "source": "https://www.sec.gov/Archives/edgar/data/1176309/000121390025111299/ea0265959-8a12b_oramed.htm",
     "title": "8-A12B — FOR REGISTRATION OF CERTAIN CLASSES"
    }
   ],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:a583dd574eeabdda61314baace0a4eae259c0b701f1e3c7b70e345de0cea9f17",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [
    {
     "date": "2022-11-21",
     "kind": "issuer-sponsored",
     "publisher": "Zacks Small-Cap Research",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://oramed.com/wp-content/uploads/2022/11/Zacks-Report-Nov.-2022.pdf",
     "state": "sourced",
     "title": null
    },
    {
     "date": "2022-04-28",
     "kind": "issuer-sponsored",
     "publisher": "Zacks Small-Cap Research",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://oramed.com/wp-content/uploads/2022/06/Zacks-Report-April-28-2022.pdf",
     "state": "sourced",
     "title": null
    },
    {
     "date": "2021-11-10",
     "kind": "issuer-sponsored",
     "publisher": "Zacks Small-Cap Research",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://oramed.com/wp-content/uploads/2022/06/Zacks_SCR_Research_November-11-2021.pdf",
     "state": "sourced",
     "title": "ORMP: Financing Enhances Flexibility to Advance Multiple Opportunities"
    },
    {
     "date": "2020-12-10",
     "kind": "issuer-sponsored",
     "publisher": "Zacks Small-Cap Research",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://oramed.com/wp-content/uploads/2022/06/Zacks-Update-Dec-2020-1.pdf",
     "state": "sourced",
     "title": null
    },
    {
     "date": "2020-12-03",
     "kind": "independent",
     "publisher": "A.G.P. / Alliance Global Partners",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://oramed.com/wp-content/uploads/2022/06/AGP-initiating-coverage-ORMP-Dec-2020.pdf",
     "state": "sourced",
     "title": "Oramed Pharmaceutical, Inc."
    },
    {
     "date": "2020-01-07",
     "kind": "issuer-sponsored",
     "publisher": "Zacks Small-Cap Research",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://oramed.com/wp-content/uploads/2022/06/Zacks-Update-Jan-7-2020.pdf",
     "state": "sourced",
     "title": "ORMP: Multiple Data Readouts on the Horizon"
    },
    {
     "date": "2019-05-07",
     "kind": "issuer-sponsored",
     "publisher": "Zacks Small-Cap Research",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://oramed.com/wp-content/uploads/2022/06/Zacks-SCR-Research-Update-May-2019.pdf",
     "state": "sourced",
     "title": "ORMP: Data from Phase 1 Trial of Oral GLP-1 in 2Q19…"
    },
    {
     "date": "2014-01-07",
     "kind": "independent",
     "publisher": "MLV",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://oramed.com/wp-content/uploads/2022/06/MLV-Initiating-Coverage-7-Jan-2014.pdf",
     "state": "sourced",
     "title": "Initiating Coverage"
    }
   ],
   "state": "found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/ORMP",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:a583dd574eeabdda61314baace0a4eae259c0b701f1e3c7b70e345de0cea9f17",
 "path": "/us/NASDAQ/ORMP",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is ORAMED PHARMACEUTICALS INC., listed on NASDAQ under ticker ORMP, with ISIN US68403P2039 and LEI 5299006K52ZIIGQJ6R84. Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States, Delaware. Its listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 63 filings in the twelve months from 2025-11-08 to 2026-11-08, across 34 filing days. The median gap between filing days is 6 days. The median latency from the latest filing to the record date is 37 days, against an exchange median of 5.0 days and a sector median of 4.0 days. The exchange median cadence gap is 6.0 days and the sector median cadence gap is 6.0 days. The latest filing is dated 2026-10-02 and is of type directors_dealings.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is Kesselman & Kesselman C.P.A.s, located in Tel Aviv, Israel. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds one lifecycle line: a listing dated 2025-11-17. It holds no delisting, no name change, and no segment move. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag is listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "No research houses were found on the issuer's own investor-relations pages read. The count is 0.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "The record holds 8 openly published research notes. Zacks Small-Cap Research published 6 of them, dated 2022-11-21, 2022-04-28, 2021-11-10, 2020-12-10, 2020-01-07 and 2019-05-07. A.G.P. / Alliance Global Partners published one dated 2020-12-03. MLV published one dated 2014-01-07.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The record holds sealed years 2021, 2022, 2023, 2024, 2025 and 2026 for this issuer. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "17 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001176309.json"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/ORMP"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "open research",
   "source": "https://oramed.com/wp-content/uploads/2022/11/Zacks-Report-Nov.-2022.pdf"
  },
  {
   "for": "open research",
   "source": "https://oramed.com/wp-content/uploads/2022/06/Zacks-Report-April-28-2022.pdf"
  },
  {
   "for": "open research",
   "source": "https://oramed.com/wp-content/uploads/2022/06/Zacks_SCR_Research_November-11-2021.pdf"
  },
  {
   "for": "open research",
   "source": "https://oramed.com/wp-content/uploads/2022/06/Zacks-Update-Dec-2020-1.pdf"
  },
  {
   "for": "open research",
   "source": "https://oramed.com/wp-content/uploads/2022/06/AGP-initiating-coverage-ORMP-Dec-2020.pdf"
  },
  {
   "for": "open research",
   "source": "https://oramed.com/wp-content/uploads/2022/06/Zacks-Update-Jan-7-2020.pdf"
  },
  {
   "for": "open research",
   "source": "https://oramed.com/wp-content/uploads/2022/06/Zacks-SCR-Research-Update-May-2019.pdf"
  },
  {
   "for": "open research",
   "source": "https://oramed.com/wp-content/uploads/2022/06/MLV-Initiating-Coverage-7-Jan-2014.pdf"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/ORMP"
  }
 ],
 "title": "ORAMED PHARMACEUTICALS INC. (ORMP) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}